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ABSTRACT In addition to conveying cellular responses to
an effector molecule, receptors are often themselves regulated
by their effectors. We have demonstrated that epinephrine
modulates both the rate of transcription of the Pradrenergic
receptor (f2AR) gene and the steady-state level of(82ARmRNA
in DDTIMF-2 cells. Short-term (30 min) exposure to epineph-
rine (100 nM) stimulates the rate of 132AR gene transcription,
resulting in a 3- to 4-fold increase in steady-state M2AR mRNA
levels. These effects are mimicked by 1 mM N6,02'-dibu-
tyryladenosine 3',5'-cyclic monophosphate (Bt2cAMP) or for-
skolin but not by phorbol esters. The half-life of the P2AR
mRNA after addition of actinomycin D (46.7 ± 10.2 min; mean
± SEM; n = 5) remained unchanged after 30 min of epineph-
rine treatment (46.8 ± 10.6 min; mean ± SEM; n = 4),
indicating that a change in transcription rate is the predomi-
nant factor responsible for the increase of P2AR mRNA.
Whereas brief exposure to epinephrine or Bt2cAMP does not
significantly affect the total number of cellular 2ARs (assessed
by ligand binding), continued exposure results in a gradual
decline in fi8AR number to :20% (epinephrine) or %45%
(Bt2cAMP) of the levels in control cells by 24 hr. Similar
decreases in agonist-stimulated adenylyl cyclase activity are
observed. This loss of receptors with prolonged agonist expo-
sure is accompanied by a 50% reduction in (32AR mRNA.
Transfection of the fi2AR promoter region cloned onto a
reporter gene (bacterial chloramphenicol acetyltransferase)
allowed demonstration of a 2- to 4-fold induction of transcrip-
tion by agents that elevate cAMP levels, such as forskolin or
phosphodiesterase inhibitors. These results establish the pres-
ence of elements within the proximal promoter region of the
132AR gene responsible for the transcriptional enhancing ac-
tivity of cAMP and demonstrate that fi2AR gene expression is
regulated by a type of feedback mechanism involving the
second messenger cAMP.
Receptor activation can stimulate or inhibit a variety of
cellular processes from basic metabolic activities to certain
highly specialized functions in differentiated tissues. Al-
though receptors serve as regulators of these cellular activ-
ities, they are themselves subject to considerable regulation.
For most receptors, stimulation is followed by a period of
reduced responsiveness or "desensitization" (1), which usu-
ally involves some combination of receptor phosphorylation,
sequestration or loss of receptor number, and uncoupling of
the receptor from the effector (2, 3). In addition to this
regulation at the protein level, the expression of the receptor
gene itself can be modulated as a consequence of activation.
In several cases (4-6) mRNA levels for the receptor are
rapidly reduced following stimulation, thereby further con-
tributing to the loss in receptor number and responsiveness,
whereas for other receptors (7, 8) expression is elevated by
processes that involve both transcriptional and posttranscrip-
tional components. In addition, complex forms of regulation
displaying early transient increases followed by a down-
regulation of expression over time have also been observed
(9, 10). Clearly, this diversity of receptor regulation must
depend upon different cell signaling pathways which them-
selves serve to regulate gene expression.
The family of G-protein-coupled receptors regulate the
intracellular concentrations of important second messenger
molecules such as cAMP, calcium, and diacylglycerol. The
.82-adrenergic receptor (2AR) is a prototypic member of the
G-protein coupled receptor family that is linked to the
stimulation of adenylyl cyclase (11, 12). The f32AR has been
shown to be a substrate for cAMP-dependent protein kinase,
resulting in a form of feedback attenuation of responsiveness
(13). In addition to these and other diverse regulatory and
metabolic effects of cAMP mediated through cAMP-
dependent protein kinase, cAMP has also been shown to
enhance the expression ofmany genes (14). In most cases this
increased gene expression is due to transcriptional activa-
tion, although in some cases mRNA stability is also affected
(15-17). The transcriptional enhancing properties of cAMP
are mediated by distinct promoter elements within the target
gene, which are termed cAMP response elements (CREs).
Most CREs contain a variation of the palindromic sequence
motif TGACGTCA, which is recognized by specific phos-
phoprotein transcription factors, some of which have been
purified (18) and recently cloned (19, 20). It is interesting to
note that many genes regulated by cAMP encode protein
products which are themselves regulated or whose secretion
is evoked by hormones that elevate intracellular levels of
cAMP (15-17, 21-24). Inspection of the 5' flanking region of
the P2AR gene from both hamster and human reveals the
presence of putative CREs, suggesting that it, too, may be
subject to regulation by cAMP at both the protein and the
transcriptional level.
Recently it has been reported that down-regulation of
32AR following long-term agonist exposure is accompanied
by a decrease in P2AR mRNA (25). In the studies reported
here, we describe changes in both .2AR gene transcription in
response to short-term agonist exposure as well as down-
regulation of 132AR mRNA levels resulting from more pro-
longed exposure. Our results suggest a form of feedback
regulation at the level of receptor gene expression that is
mediated by the second messenger cAMP.
Abbreviations: 182AR, f2-adrenergic receptor; CAT, chlorampheni-
col acetyltransferase; CRE, cAMP response element; CYP, cyano-
pindolol; DMF, dimethylformamide; DMSO, dimethyl sulfoxide;
IBMX, isobutylmethyixanthine; PMA, phorbol 12-myristate 13-ace-
tate; Bt2cAMP, N6,02-dibutyryladenosine 3',5'-cyclic monophos-
phate; EGF, epidermal growth factor.
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MATERIALS AND METHODS
Cell Cultures, Transfections, and Chloramphenicol Acetyl-
transferase (CAT) Assays. DDT1MF-2 hamster smooth mus-
cle cells were grown in suspension culture as described (26).
Experiments were initiated at a cell density of =2.2 x 105
cells per ml. Catecholamines were added to cells in the
presence of superoxide dismutase and catalase (1 ,ug/ml final
concentration) to prevent catecholamine oxidation (27).
Monolayer cultures of rat C6 glioma cells were grown in
Dulbecco's modified Eagle's medium/Ham's F-10 medium
(50:50) supplemented with 10% fetal bovine serum. Trans-
fections of C6 glioma cells were performed with calcium
phosphate precipitates (28) containing 10 ,tg of test plasmid
DNA. Cells were incubated with the precipitate for 4 hr,
treated with 15% glycerol for 2 min, and supplemented with
fresh medium. After 24 hr, forskolin (in ethanol), isobutyl-
methylxanthine [IBMX; in dimethylformamide (DMF)], or
phorbol 12-myristate 13-acetate [PMA; in dimethyl sulfoxide
(DMSO)] was added to cells at a final concentration of25 ILM,
0.25 mM, or 100 nM, respectively. Cell extracts were pre-
pared 15-18 hr after the addition ofdrugs by freezing-thawing
as described (29). Protein concentrations of the extracts were
determined by the method of Bradford (30). CAT assays,
containing 50-100 ,ug of protein, 0.3 uCi of [14C]chlor-
amphenicol (54 Ci/mmol; 1 Ci = 37 GBq; Amersham), and
1.1 mM acetyl-CoA in a final volume of 150 IlI, were
incubated for 60 min at 37°C, extracted with ethyl acetate,
and chromatographed (29).
Plasmid Constructions. The vector for all CAT constructs
was p-L-CAT-2, which was obtained from Russell Kaufman
(Duke University). For the /2AR promoter clone pl.4, a
1440-base-pair (bp) HinfI fragment from nucleotide -1355 to
+85 relative to the transcription initiation site (31) was
isolated by gel electrophoresis. Overhanging 5' ends were
filled in with the Klenow fragment ofDNA polymerase I and
excess dNTPs and were ligated into the Sma I site in the
polylinker of the CAT-containing vector p-L-CAT-2. Simi-
larly, for (82AR clone p0.3, a 305-bp Alu I fragment from
nucleotide -235 to +70 was isolated and ligated into the Sma
I site of p-L-CAT-2. The clones were verified with respect to
their orientation and integrity by restriction mapping and
DNA sequencing.
Radioligand Binding and Adenylyl Cyclase Assays. Prepa-
ration of plasma membranes, binding of the ,BAR-specific
ligand 125I-labeled cyanopindolol (125I-CYP), and adenylyl
cyclase assays were performed as outlined (26).
RNA Analysis. Total cellular RNA was isolated from
DDT1MF-2 cells by the cesium chloride gradient method (32).
Following denaturation by glyoxalation and fractionation by
electrophoresis, the RNA was immobilized on nylon mem-
branes and hybridized to P2AR and actin cDNA probes, all
as previously detailed (26).
For nuclear run-off transcription assays, DDT1MF-2 cells
were harvested by centrifugation and washed in a buffer
containing 5 mM Tris (pH 7.5) and 1.5 mM MgCl2. Nuclei
were prepared, counted, and used immediately without freez-
ing (1-3 x 107 per incubation). Subsequent steps of [32P]RNA
isolation and hybridization were performed exactly as de-
scribed (26). Following autoradiography, radiolabeled spots
were cut out and assayed for radioactivity. The synthesis
rates were calculated from [32P]RNA bound to the specific
cDNAs minus radioactivity bound to the pGEM control and
corrected for the amount of input labeled RNA in millions of
cpm. The parts per million (ppm) for /82AR synthesis were
normalized to 8-actin ppm values.
RESULTS
Following the addition of 100 nM epinephrine to DDT1MF-2
cells, there was a rapid increase in the steady-state level of
f32AR mRNA. This 3- to 4-fold increase in the level of /2AR
mRNA was evident 30-60 min after addition of the hormone
(Fig. 1). No change in actin mRNA was apparent. The major
hybridizing band at 2.2 kilobases (kb) and the minor band at
1.8 kb have been observed previously (26) and most likely
result from the use of two poly(A) signals =400 bp apart.
Since these two mRNA species varied in parallel, they were
analyzed together. Over prolonged exposure, a steady de-
cline in 2AR mRNA levels is evident such that by 24 hr,
levels are reduced >50% below the pretreatment level.
Despite the stimulation of P2AR mRNA levels, receptor
levels (Fig. 2), as measured by the binding of the antagonist
1251-CYP, were not changed during the first few hours. In
some experiments slightly elevated levels of receptor were
found 30 min after addition ofthe catecholamine, but this was
not statistically significant. Prolonged exposure led to the
typical agonist-promoted down-regulation of receptors (1) to
=20%o of pretreatment levels within 24-28 hr. Results from
whole cell binding experiments were essentially identical to
the results obtained in plasma membranes (M.B. and S.C.,
unpublished observations). Cells that received only the me-
dium vehicle displayed no changes in receptor number or
mRNA accumulation (not shown).
The role of cAMP in the transient stimulation of 182AR
mRNA levels was investigated by treating cells with N6,02'_
dibutyryladenosine 3',5'-cyclic monophosphate (Bt2cAMP)
(1 mM) and the phosphodiesterase inhibitor IBMX (0.25
mM). f32AR mRNA levels were regulated by Bt2cAMP in a
fashion similar to that induced by epinephrine (Fig. 3A). A
2.5- to 3-fold increase in 132AR mRNA was observed 1.5 hr
after exposure to the drug. This enhancement rapidly re-
turned to control levels, whereupon there was a further
decline to =30% of initial levels. By 24 hr, transcript levels
began to recover. Again, in contrast to the stimulation of
132AR mRNA, the number of f32ARs was unchanged during
the first few hours, with an ultimate decline to 45% of
pretreatment levels (Fig. 3B) occurring by 24 hr.
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FIG. 1. Time course of changes in p2AR mRNA levels after
addition of epinephrine. Total cellular RNA was prepared from
DDT1MF-2 cells immediately before (O hr) or at the indicated times
after addition of epinephrine (100 nM). Northern blots were pre-
pared, and the levels of (32AR and actin mRNAs were analyzed by
scanning the autoradiograms with a laser densitometer. .32AR mRNA
levels (with 0 hr defined as 100%o) are expressed relative to actin
mRNA, as actin expression is unaffected by epinephrine. The data
shown are the average ± SEM of three experiments. (Inset) Repre-
sentative Northern blot.
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FIG. 2. Time course of changes in ,32AR number in plasma
membranes from DDT1MF-2 cells after addition of epinephrine.
Cells were harvested immediately before (0 hr) or at the indicated
times after addition of epinephrine (100 nM). Plasma membranes
were prepared and f32AR density was determined by binding of the
antagonist 1251-CYP. The data shown are the average ± SEM ofthree
experiments.
The induction ofP2AR mRNA levels was specific to (2AR
activation and cAMP generation. The effect of epinephrine
was mediated through the f32AR rather than the a1-adrenergic
receptor (ajAR) on these cells, since propranolol, a P2AR
antagonist, blocked the increase in 82AR mRNA, whereas
phentolamine, an a1AR-specific antagonist, did not. As ex-
pected, isoproterenol, a OAR-specific agonist, increased
I32AR mRNA levels as early as 10 min after its addition (not
shown).
Changes in the steady-state level of expression of a gene
result from alterations in either the rate of transcription, the
rate of degradation of the message, or a combination of the
two processes. For several genes, there is evidence for
cAMP-mediated changes in both of these pathways (15-17,
22). We therefore investigated the mechanisms underlying
the cAMP-induced elevation of 82AR mRNA levels that
occurs soon after exposure to agents that elevate cAMP
levels. Nuclear run-off transcription assays were employed
to monitor changes in the rate of transcription of the 32AR
and actin genes in DDT1MF-2 cells treated with 100 nM
epinephrine or medium vehicle alone. In addition, total RNA
was prepared from aliquots of cells so that the transcription
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FIG. 4. Relative transcription
C E rate of the 182AR gene in control
_ _ _ (C) or epinephrine-treated (E)
cells assessed by nuclear run-off
- transcription assay. Nuclei were
prepared 30 min after addition of
medium vehicle or epinephrine
(100 nM) and incubated in the pres-
ence of 200 gCi of [a-32P]UTP.
The [32P]RNA was isolated and
hybridized to plasmid DNAs (10
ltg per slot) containing /32AR or
actin cDNA inserts or without in-
sert (pGEM). Following autoradi-
ography, radiolabeled spots were
cut out and assayed for radioac-
tivity. Background hybridization
to pGEM was subtracted from
values for (82AR and actin. The
fold increase in 82AR transcrip-
tion (1.77 ± 0.11; mean ± SEM;
n = 3; P < 0.01) was essentially
identical whether determined by
laser scanning or scintillation
spectroscopy and was comparable
to the increase in steady-state(32AR mRNA (2.35 ± 0.66; mean
_-I-- - + SEM; n = 3; P < 0.025) deter-
C E mined from Northern blots.
rate measured in a given experiment could be compared
directly to the change in steady-state message levels. The
results ofthis series ofexperiments are depicted in Fig. 4. The
rate of f32AR gene transcription was nearly doubled in nuclei
from cells pretreated with epinephrine for 30 min, whereas
the rate of actin gene transcription was essentially un-
changed. The enhancement of 12AR gene transcription ob-
served (1.77 ± 0.11; mean ± SEM; n = 3) is in reasonable
agreement with the fold increase in the steady-state levels of
(32AR mRNA in these experiments (2.35 ± 0.66; mean +
SEM; n = 3) determined by Northern blotting. Thus the rapid
increase in 132ARmRNA levels induced by cAMP is the result
of enhanced transcription of the 832AR gene.
This conclusion was supported by additional experiments
that examined the half-life ofthe 32AR mRNA. After a 30-min
incubation with either 100 nM epinephrine or medium alone,
actinomycin D was added (1 ,g/ml final concentration), and
the disappearance of steady-state f32AR mRNA was moni-
tored at timed intervals (Fig. 5). Although P2AR transcripts
were more abundant in cells treated with epinephrine for 30
min than in the untreated cells, the rate at which this mRNA
decayed (tl/2 = 46.8 ± 10.6 min; mean ± SEM; n = 4) was
unchanged relative to the untreated control cells (t1/2 = 46.7
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FIG. 3. Time course of changes in /32AR
mRNA levels and receptor number induced by
Bt2cAMP. (A) 132AR mRNA levels. Northern
blots were prepared from total cellular RNA
after addition of Bt2cAMP (1 mM) and IBMX
(0.25 mM). Autoradiograms were analyzed by
scanning laser densitometry, and 82AR mRNA
levels are expressed relative to actin mRNA
(with 0 hr defined as 100%). The data shown are
the average ± SEM of three experiments. (B)
Ij...wI. 832AR density in plasma membranes was as-
20 24 sessed by the binding of 125I-CYP. The results
presented are the average of three experiments.
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FIG. 5. Estimation of the half-life of the H2AR mRNA in
DDT1MF-2 cells in the presence or absence of epinephrine. Thirty
minutes after addition of medium (CTRL, n) or 100 nM epinephrine
(EPI, *) actinomycin D was added to both cultures to a final
concentration of 1 ug/ml. Total cellular RNA was prepared from
aliquots of cells collected at 10-min intervals, and Northern blots
were prepared. The autoradiograms were scanned and the data were
fit by least-squares linear regression analysis. The slopes for the two
groups were compared by a two-tailed t test. This analysis was
confined to the more abundant upper hybridizing band only since it
was not always possible to accurately measure the lower band due
to background hybridization in that region. In a few experiments
where a clear analysis was possible, the ti/2 of the lower band was
"80 min. (Inset) Representative Northern blot of P2AR mRNA.
± 10.2; mean ± SEM; n = 5). The 1.8-kb mRNA appeared
to decay with slower kinetics, such that at later times it
became the predominant species.
For many genes that are transcriptionally regulated by
cAMP, the 5' flanking promoter regions are necessary and
sufficient to carry out this activity (14). Within these regions
specific sequences have been identified as critical for this
function and are termed CREs. In the promoter regions ofthe
J32AR gene from hamster and human, sequences that conform
to the CRE consensus are present between -50 and -60 from
the start site of transcription. We therefore constructed
promoter-reporter gene fusions between the 5' flanking re-
gion of the human 182AR and the coding sequences of the
bacterial CAT gene. The test plasmids contained P2AR
promoter sequences extending -1355 (pl.4) or -235 (p0.3)
bp upstream from the transcription start site. These con-
structs were introduced by DNA-mediated gene transfer (28)
into rat C6 glioma cells. Fig. 6 demonstrates that CAT
activity of both constructs is enhanced 2- to 4-fold over basal
expression by forskolin plus IBMX or IBMX alone but not by
PMA. Forskolin also stimulates CAT activity when these
constructs are transfected into a human T-cell line (S.C. and
Dean Ballard, unpublished observations). These results es-
tablish that the promoter region of the P2AR contains ele-
ments responsible for the transcriptional enhancing activity
ofcAMP as observed by nuclear run-offtranscription assays.
DISCUSSION
Our results document a transient ,8-agonist stimulated,
cAMP-mediated increase in the steady-state level of 82AR
mRNA resulting from an increase in the rate of transcription
of the J2AR gene. A corresponding increase in the number of
cellular f32ARs was not detected, however. This likely rep-
resents the net result of simultaneous disappearance of
receptors (e.g., by sequestration and degradation) and syn-
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FIG. 6. cAMP stimulation of CAT enzyme activity in C6 glioma
cells transfected with 182AR 5' flanking sequences: Schematic dia-
gram of the 182AR gene indicating the location and sequence of the
putative CRE at -58 bp relative to the start site of transcription
(arrow). C6 glioma cells were transfected with CAT plasmid DNAs
containing 1335 bp (pl.4) or 235 bp (pO.3) of human P2AR 5' flanking
DNA (10 ,ug of DNA per 100-mm dish) by the calcium phosphate
precipitation method. CAT enzyme activity was measured in cell
extracts 18-20 hr after addition of forskolin (FSK) (25 mM), IBMX
(0.25 mM), orPMA (100 nM). The data shown are the average offour
separate experiments, each performed in duplicate. Slight differ-
ences in CAT activity observed between p1.4 and pO.3 in response
to IBMX plus forskolin were not significant by a t test (P < 0.05).
thesis of new receptors. This would preclude detection of a
significant rise in (32AR by ligand-binding techniques. Con-
sistent with this formulation, in cells transfected with a /2AR
cDNA lacking the 5' regulatory regions, the rates of agonist-
or cAMP-induced down-regulation of the f32AR are consid-
erably faster than those observed here (M.B., S.C., and Paul
Campbell, unpublished observations). A similar situation has
been encountered in earlier studies of epidermal growth
factor (EGF) receptor regulation following agonist exposure
(8). In this case, ligand-bound EGF receptor internalization
and degradation were occurring while receptor mRNA levels
were increasing, thus preventing detectable increases in EGF
receptor number. Analogous processes may be occurring for
the 182AR.
The EGF receptor paradigm highlights an important fea-
ture of signal transduction in general: that cells maintain
stringent control over hormonal responsiveness by regulating
multiple steps in the signal transduction pathway. Mecha-
nisms exist to regulate both receptor-effector coupling and
receptor number. For the j32AR, within minutes of agonist
exposure, receptors are rapidly uncoupled and sequestered
from their effector, adenylyl cyclase, with receptor phos-
phorylation participating in this process (1-3). From a phys-
iological perspective, most neural and endocrine tissues on
which these receptors reside receive brief, periodic bursts of
hormone. In these cells the signal transduction apparatus
must be flexible enough to respond to repeated stimulation.
Transient stimulation of P2AR synthesis, mediated by the
second messenger cAMP, may be an important element in
maintaining this cellular responsiveness.
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Most genes that are transcriptionally regulated by cAMP
have relatively short-lived mRNAs (minutes vs. hours; ref.
14). Our data estimate the half-life for the (82AR mRNA in
DDT1MF-2 cells to be -45 min, consistent with this regula-
tory paradigm. This estimate, however, differs dramatically
from the value of 12 hr recently reported by Hadcock and
Malbon (33). The reasons for this discrepancy are not clear
but might include the following: (i) our DDT1MF-2 cells were
grown as a suspension culture, whereas Hadcock and Malbon
maintained this cell line in monolayer culture, and (ii) dif-
ferent methods ofRNA analysis were used (Northern blotting
with <25 ,ug of total cellular RNA in our case vs. solution
hybridization and filter binding by Hadcock and Malbon with
150 ,ug of RNA).
Quantitatively, the effect of cAMP on the increase in the
transcription rate of the 32AR gene is similar to that observed
for other cAMP-regulated genes such as the glycoprotein
hormone a-subunit gene (22), phosphoenolpyruvate carboxy-
kinase (16), tyrosine aminotransferase (17), and lactate de-
hydrogenase (15). The presence of CREs in the promoters of
these genes (21-24) has been shown to be responsible for this
stimulation. For the ,82AR gene, transcriptional enhancement
may also be mediated by a CRE within the promoter region.
The results from transient transfection of P2AR promoter-
CAT constructs into C6 glioma cells, which yield a 2- to 4-fold
stimulation of CAT activity in response to forskolin and
IBMX, fully support the results of nuclear run-off transcrip-
tion assays. The extent of induction by these agents is similar
for both constructs (pl.4 and p0.3), indicating that the
sequences responsible for transcriptional enhancement are
present within the proximal 235 bp ofP2AR 5' flanking DNA.
As shown in Fig. 6, the sequence GTACGTCA appears
within this region (-58) in both the human and hamster p2AR
genes and displays close homology to these other CREs (14,
21-24). More detailed study of this region by mutational
analysis and other approaches aimed at identifying sequences
that may be specifically recognized by cAMP-regulated nu-
clear factors (19, 20) should allow the characterization of this
element more precisely.
We have not focused here on the observation, made both
in these studies and by others (25), that prolonged exposure
of cells to agonist results in a decrease in 32AR mRNA. This
area, however, also requires further studies to establish a
comprehensive understanding of the mechanisms of desen-
sitization and down-regulation of the f2AR. Recent studies
(25) have shown that cAMP is involved in this down-
regulation of P2AR mRNA levels, but as yet no mechanism
has been described to explain this observation. For several
other cAMP-regulated genes that display early and transient
accumulation of mRNA, dynamic changes in both the tran-
scription rate and mRNA stability occur. For example, in the
case of the tyrosine aminotransferase gene in particular,
temporally distinct changes in the transcription rate and in
the turnover of tyrosine aminotransferase mRNA have been
observed, depending upon the duration of exposure to cAMP
analogues (17). This type of complex regulation may also
exist for the P2AR gene during down-regulation. Recently,
we have obtained evidence from cells transfected with a
human 832AR cDNA for cAMP-mediated changes in 132AR
mRNA levels that are distinct from transcriptional effects
(M.B. and S.C., unpublished observations), suggesting alter-
ations in mRNA turnover.
Our results establish that the expression of the P2AR gene
is regulated by its second messenger, cAMP. Like other
cAMP-regulated genes, elements within the 5' flanking region
of the gene mediate this transcriptional enhancement by
cAMP. To our knowledge, this form ofregulation, which may
represent a physiologically important feedback mechanism
for maintaining hormonal responsiveness, has not been found
previously for an adenylyl cyclase-coupled receptor.
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